NCT04861948: IBI188 Combination Therapy in Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Chemotherapy, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior CD47 antibody, SIRPa antibody, CD47/SIRPa recombinant protein, or PD-1/L1 inhibitors (e.g. Tecentriq/atezolizumab, Keytruda/pembrolizumab)

Comments are closed.

Up ↑